Purdue's $8.3bn Settlement With DOJ Requires Reconstitution As Public Benefit Company
Executive Summary
Purdue pleads guilty to three felony charges over marketing of OxyContin under settlement that requires Purdue to be dissolved and transformed into an entity that provides addiction and overdose medicines. Twenty-five state AGs oppose creation of a PBC, arguing Purdue should be sold to another company.
You may also be interested in...
Biogen Agrees To One Of Largest FCA Settlements Without DOJ Intervention
Company to pay $900m to resolve claims it paid kickbacks to physicians to induce them to prescribe its multiple sclerosis drugs. Whistleblower sought damages based on the number of prescriptions written after a healthcare provider received a kickback from Biogen.
US FDA Cast As Culpable Player In Opioid Epidemic In Hulu’s Dopesick Series
Show depicts former agency officials approving OxyContin labeling that enabled Purdue to market it as nonaddictive and subsequently refusing pleas to restrict its use.
Mandatory Prescriber Education For Opioids; Is This The Time?
US FDA is once again asking whether its opioid Risk Evaluation & Mitigation Strategy program for opioids should make continuing education requirements mandatory for prescribers. This time there may be no choice but to move forward with the plan.